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Trp53 mouse germline 
knockout.
Trp53−/− homozygous: 100% tumor penetrance 
at ?4.5 months. Typical tumors: T cell lymphoma 
(>60%); soft tissue sarcoma (?25%); osteosar-
coma, brain tumors, teratoma (together <15%); 
carcinomas rarely observed. Trp53+/− heterozygous: 
50% tumor penetrance at 17 months. Typical 
tumors: T cell lymphoma (?30%); soft tissue 
sarcoma (?30%); osteosarcoma (?30%); more 
carcinomas than Trp53−/− mice.
Oncogenic cooperativity observed between 
Trp53−/− and other lesions such as Rb−/− or Eµ-Myc. 
 Carcinogenesis induced by different genotoxic agents 
or irradiation is accelerated in Trp53-deficient mice. 
Mutations in TP53 found in more than 
50% of all human tumors. 
Trp53 point mutation 
knockin mice express 
Trp53 (R172H) or Trp53 
(R270H) from the endog-
enous locus. 
Tumor spectra differ from germline Trp53 knockout 
mice with more carcinomas, B cell lymphomas, 
endothelial tumors.
In mice, Trp53 (R172H) and Kras (G12D) cooperate 
to promote chromosomal instability and metastatic 
pancreatic ductal adenocarcinoma.
Li-Fraumeni syndrome patients have 
TP53 point mutations rather than 
deletions, so knockin mice are better 
models of this disease.
Conditional Trp53 knock-
out mice carry loxP sites 
in introns 1 and 10 of the 
Trp53 locus.
Homozygous mice are not tumor prone. When 
crossed with mice expressing Cre in the germline, 
wild-type Trp53 allele is excised and mice develop 
the same tumor spectrum as Trp53 germline 
knockout mice.
These mice develop breast cancer when crossed with 
Brca2 conditional knockout mice and K14-Cre mice. 
When crossed with Rb1 loxP/loxP mice, small-cell 
lung cancer results after treatment with Adeno-Cre 
and deletion of the two tumor suppressor genes.
Breast cancer is the second most 
frequent cause of death among US 
women. 1 in 27 women dies of breast 
cancer. Small-cell lung cancer ac-
counts for ?20% of all lung cancers.
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Ink4a/Arf germline 
knockout mice carry a 
deletion of exon 2/3 of the 
Ink4a/Arf (Cdkn2a)  locus 
eliminating both p16 
(Ink4a) and p19 (Arf).
Homozygous mice develop sarcomas (50%) 
and B cell lymphomas (50%) by ?32 weeks. In 
 heterozygous animals, tumors appear with lower 
penetrance and longer latency and uniformly dem-
onstrate loss of the wild-type allele.
Loss of Ink4a/Arf cooperates with oncogenes 
expressed from tissue-specific promotors, such as 
tyrosinase-Ras (melanomas) and Eµ-Myc (B cell 
lymphomas). EGFR, if delivered in a retrovirus to glia, 
induces formation of gliomas in Ink4a/Arf homo- and 
heterozygous mice.
Inactivation of the INK4a/ARF locus 
is one of the most common lesions in 
various human tumors and can arise 
from homozygous deletions (14%), 
point mutations (5%), or promoter 
methylation (20%).
Arf germline knockout 
mice lack p19 (Arf) due 
to deletion of exon 1β 
but express normal p16 
(Ink4a).
80% of homozygous mice develop sarcomas 
(43%), T cell lymphomas (29%), carcinomas (17%), 
and neurological tumors (11%) by ?38 weeks. 
Tumors in heterozygous mice are less frequent and 
are accompanied by loss of the wild-type allele.
Like loss of Trp53, Arf deficiency accelerates tumori-
genesis induced by various mitogenic oncogenes, 
implicating Arf as a crucial mediator of oncogene 
signaling and a component of a cellular failsafe 
mechanism that counters hyperproliferative signals.
Ink4a germline knockout 
mice lack p16 (Ink4a) but 
express p19 (Arf).
?25% of the homozygous mice develop tumors 
(mainly sarcomas and lymphomas) by ?44 weeks.
Ink4a knockout mice are prone to chemically induced 
carcinogenesis. Recent studies have implicated p16 
in stem cell aging.
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Conditional Lox-STOP-
Lox-Kras2 (G12D) mice 
(LSL-Kras) express an 
activating mutant Kras 
allele from its endogenous 
locus after Cre-medi-
ated excision of a STOP 
cassette.
Non-small-cell lung cancer (adenocarcinoma) pro-
duced by intranasal administration of Adeno-Cre.
Trp53 loss or mutation strongly promotes progres-
sion of Kras(G12D)-induced lung adenocarcinomas, 
yielding invasive desmoplastic tumors that metas-
tasize early and resemble advanced human lung 
adenocarcinomas.
Adenocarcinoma is the second most 
common type of non-small-cell lung 
cancer (after squamous cell carci-
noma) and has increasing incidence 
rates.
Pancreatic cancer produced by crossing with  
Pdx-1-Cre transgenic mice.
Activated Kras and Ink4a/Arf deficiency cooperate to 
produce metastatic pancreatic ductal adenocarcino-
ma with similar genetics and histopathology to human 
pancreatic cancer.
Pancreatic cancer is fourth leading 
cause of cancer death in US; there is 
no effective treatment. Mutations in 
KRAS in ?90% of pancreatic cancers. 
Myeloproliferative Disease (MPD) produced by 
crossing with Mx1-Cre mice and pI-pC treatment. 
Acute myeloid leukemia (AML) is as-
sociated with activating lesions in RAS 
signaling networks in ?60% of cases. 
There are 12,000 new patients/year in 
the US, with only a 30% cure rate.
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Pten germline knockout. Homozygosity for the null Pten mutation results 
in embryonic lethality (E9.5). Pten+/− mice develop 
multiple tumor types (breast, thyroid, endometrium, 
prostate, and T cell lymphoma).
Breast carcinoma development is accelerated in 
Pten+/− × MMTV-Wnt1 mice, less so in MMTV-Wnt1 
mice. Only Pten+/− × Cdkn1b−/− mice but not Pten+/− 
mice rapidly develop prostate carcinomas at complete 
penetrance. Pten haploinsufficiency enables tumori-
genesis. 
The PTEN tumor suppressor is 
mutated in human carcinomas (e.g., 
breast, prostate, and endometrium) 
and in glioblastoma. Cowden disease 
patients have PTEN mutations and 
increased cancer risk.
Conditional Pten 
knockout mice (Cre-loxP 
system).
Prostate-specific knockout of Pten by crossing with 
probasin-Cre (PB-Cre) mice leads to induction of 
senescence, which delays development of prostate 
cancer (median onset after 4–6 months).
Senescence is bypassed in PB-Cre × Pten loxP/loxP 
× Trp53 loxP/loxP compound mutant mice leading to 
rapid tumor development after puberty. 
Prostate cancer is the second leading 
cause of cancer-related death in US 
males.
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Eµ-Myc mice express 
Myc in the B cell lineage 
under control of the im-
munoglobulin heavy chain 
enhancer (Eµ).
Mice develop Burkitt-like lymphoblastic B cell 
lymphoma, diffuse large B cell lymphoma, and 
plasmacytoma at 2–6 months of age.
Oncogenic cooperativity with other lesions (e.g., 
overexpression of Bcl-2, loss of Arf or Trp53). This 
cooperativity establishes oncogene-induced apopto-
sis as a primary barrier against tumorigenesis and a 
determinant of response to treatment. Insertional mu-
tagenesis screens using Mo-MLV in Eµ-Myc mice led 
to discovery of oncogenes such as Bmi1 and Pim1.
B cell non-Hodgkin lymphoma, the 
most common form of lymphoma, 
affects ?300,000 patients in the US 
(40% die within 5 years). Under-
standing heterogeneity in treatment 
response is a challenge for improving 
lymphoma therapy. 
Conditional tet-o-Myc 
mice harbor Myc under 
control of the tetracycline-
responsive element (TRE).
Various tumors generated by crossing tet-o-Myc 
mice with tissue-specific tet-transactivator (tTA or 
rtTA) mice: liver carcinoma (LAP-tTA mice); T cell 
lymphoma, acute myeloid leukemia, and sarcoma 
(EµSR-tTA); breast adenocarcinoma (MMTV-rtTA). 
Reversible expression of Myc boosts understand-
ing of oncogene addiction (tumor regression after 
withdrawal of the causative oncogene) and tumor 
dormancy (blocking of causative oncogenes allows 
cancer cells to survive in a nonproliferative state).
Hepatocellular carcinoma is the fifth 
most common cancer worldwide 
and the third leading cause of cancer 
death due to lack of treatment options.
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directs expression of 
SV40 T antigen (Tag) in 
β cells of the endocrine 
pancreas.
Sequential development of hyperplasia, angiogenic 
hyperplasia, adenomas, and invasive carcinomas of 
pancreatic islets.
Complete early penetrance plus multifocal disease 
enable detailed characterization of the different stages 
of tumor development and the role of angiogenesis.
The model is widely used for preclini-
cal drug testing.See online version for references.838 Cell 129, May 18, 2007 ©2007 Elsevier Inc. DOI 10.1016/j.cell.2007.05.013 
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Genetically defined mouse models of human cancer provide a tractable experimental system for studying cancer genetics, pathol-
ogy, and therapy in a physiological environment. For this SnapShot, we have selected mouse models of human cancers according 
to whether the models have made major contributions to understanding the function of a particular cancer gene or mechanisms of 
tumorigenesis (e.g., tumor suppressor p53 knockout mice and RIP-Tag mice). Whenever possible, we discuss models that accurately 
resemble major clinical tumor types. For more information about available models visit the website of the Mouse Models of Human 
Cancers Consortium (MMHCC, http://emice.nci.nih.gov).
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